Avidity Biosciences, Inc. , a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCstm), today announced that the Japan ...

Mexiletine appears to be safe and is likely an effective treatment for managing symptoms of myotonia (delayed muscle relaxation after a contraction) in people wit ...

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted regulatory approval for a label expansion of KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in a combination ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2025 financial results on Monday, May 5, ...

Building on initial awards totalling over £1.6m, a team of researchers are receiving further investment to explore the capabilities of quantum ...

Avidity Biosciences, Inc.’s RNA share price has surged by 11.33%, which has investors questioning if this is right time to sell.

Dyne Therapeutics, Inc.’s DYN share price has dipped by 11.76%, which has investors questioning if this is right time to buy.